oral sel. PDE2A phosphodiesterase inhibitor
for cognition, target engagement in brain
from HTS, SBDD, and FEP claculations
J. Med. Chem., Oct. 26, 2020
Janssen Pharmaceutica NV, Beerse, BE
“compound 46” (Janssen oral selective brain-penetrant PDE2A phosphodiesterase inhibitor)